A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer

Status:
Completed

Trial end date:
2017-10-01

Target enrollment:

Participant gender:

This is an open label, Phase 1, dose escalation and dose confirmation study of ZEN003694 in patients with mCRPC.

Phase 1

Zenith Epigenetics